Back to Search
Start Over
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
- Source :
- Cardiovascular & Hematological Disorders-Drug Targets. 21:88-90
- Publication Year :
- 2021
- Publisher :
- Bentham Science Publishers Ltd., 2021.
-
Abstract
- After the outbreak of COVID-19, many novel drugs have been introduced to improve patients’ conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
- Subjects :
- medicine.medical_specialty
2019-20 coronavirus outbreak
Heart Diseases
Coronavirus disease 2019 (COVID-19)
Side effect
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Favipiravir
Antiviral Agents
Humans
Medicine
Intensive care medicine
Beneficial effects
Pharmacology
Alanine
SARS-CoV-2
business.industry
Outbreak
Hematology
General Medicine
Amides
Adenosine Monophosphate
COVID-19 Drug Treatment
Pyrazines
Molecular Medicine
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- ISSN :
- 1871529X
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Cardiovascular & Hematological Disorders-Drug Targets
- Accession number :
- edsair.doi.dedup.....4d289af6ebfc7fb0be28a27facdbbf84
- Full Text :
- https://doi.org/10.2174/1871529x21666210812103535